Knowledge Partners

 Economic Laws Practice       Avalon Consulting

 Technloogy Holdings   

April 07, 2014

Sun keeps media in the dark on the Ranbaxy deal

"Sun Pharma bought Ranbaxy for $4 Billion? Holy Shit!" It was clear that this Private Equity fund manager hadn't heard of the deal as of 9.30 am on Monday, April 7. "It's indeed the top story in the Venture Intelligence Deal Digest Daily Newsletter that is just being sent out," said yours truly. No journalist had managed to squeeze in anything about the deal as of Monday morning. Thankfully, a colleague noticed the BSE release filed by Sun Pharma before we went to press. And it was clear that our newsletter was the first instance that a lot of subscribers were hearing about the mega transaction.

Given that both the buyer and seller are publicly traded, this is exactly how it should be - ie, the stock exchanges should be the first to hear about the deal. Contrast this with the number of times another transaction involving a listed company - the buyout of hydel assets of Jaypee Group's by Abu Dhabi's Taqa - got reported in the media before the official deal announcement. So much so, when the deal was officially announced it was news to nobody. Such leaking seems endemic among most infrastructure sector company transactions. The Sun-Ranbaxy deal has clearly shown the even mega transactions can be kept quiet until closure. Hope the infra companies learn how.

Venture Intelligence is the leading provider of data and analysis on Private Company Financials, Transactions (private equity, venture capital and M&A) & their Valuations in India. Click Here to view our products list including the Free Deal Digest Weekly: India's First & Most Exhaustive Transactions Newsletter.